Company Overview: Boston Therapeutics

Industry News

22 Sep

Boston Therapeutics (BTHE) Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center for Phase III Study of BTI-320

360 Patients to Be Enrolled in Phase III Study at 10 Sites in Four Countries; BTI-320, a Non-Systemic Chewable Tablet, Represents a New Generation of Alpha Glycosidase Inhibitors Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), a developer of complex carbohydrate therapeutics to treat diabetes, has signed...

Read more

16 Sep

Boston Therapeutics to Present Findings of BTI-320 as Therapy for Glycemic Control at 50th Annual Meeting of European Association for the Study of Diabetes

Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its lead drug candidate, as a poster presentation at the 50th Annual Meeting of the European Association for the Study of Diabetes...

Read more

8 Aug

Boston Therapeutics (BTHE) Reports Corporate Update and Financial Results for the Second Quarter Ended June 30, 2014

Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, reports its financial results for the second quarter and six months ended June 30, 2014. David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, “During the quarter, we...

Read more

5 Aug

Boston Therapeutics (BTHE) Expands Medical Advisory Board

Noted Diabetes Experts Meng H Tan, M.D., Philip Raskin, M.D., and Charles M. Clark, Jr., M.D. to Serve as Medical Advisory Board Members Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), a developer of complex carbohydrate therapeutics to treat diabetes, has expanded its Medical Advisory Board with the...

Read more

9 Jul

Boston Therapeutics (BTHE) Appoints Benjamin Rivnay, Ph.D. to Chief Scientist

Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the Company’s science and technology....

Read more

27 May

Boston Therapeutics (BTHE) to Present at SeeThruEquity Microcap Investor Conference on May 28 and Marcum Microcap Conference on May 29

Boston Therapeutics, Inc. (BTI) (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, today announced that President Kenneth A. Tassey, Jr. will present at two upcoming conferences. Mr. Tassey will provide an overview of the Company, recent business developments and growth strategy. At the...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address